Medtronic’s shares increase after posting quarterly revenue growth
For the third quarter of fiscal year 2017, Medtronic’s revenue increased 5 percent of $7.283 billion, GAAP net income decreased 25 percent to $821 million and diluted earnings declined 23 percent to $1.12 per share compared with the same time period a year ago.
The fiscal third quarter ended on Jan. 27, 2017. Medtronic announced the results Feb. 21.
As of midday on Feb. 21, Medtronic’s stock price increased around 2 percent to $80.49 per share.
During the quarter, revenue increased 5 percent to $2.548 billion in the cardiac and vascular group, increased 5 percent to $2.147 billion in the minimally invasive therapies group, increased 4 percent to $1.817 billion in the restorative therapies group and increased 6 percent to $501 million in the diabetes group.
Within the cardiac and vascular group, revenue increased 7 percent to $1.371 billion in the cardiac rhythm and heart failure division, increased 2 percent to $751 million in the coronary and structural heart division and increased 6 percent to $426 million in the aortic and peripheral vascular division.
Medtronic mentioned a few drivers of its revenue growth in the cardiac and vascular group, including its acquisition last year of HeartWare International, Inc. and the U.S. launches of the CoreValve Evolut R 34 mm transcatheter aortic heart valve and the HawkOne 6 French directional atherectomy system.
Medtronic also provided updated guidance for fiscal year 2017. The company expects revenue growth within the mid-single digit range, diluted non-GAAP earnings per share growth in the double digits and free cash flow of $5 billion to $6 billion.